Biogen Shares Positive Alzheimer’s Trial Results
CAMBRIDGE, Mass., July 14, 2026 Biogen announced positive Phase 2 CELIA study results demonstrating that investigational antisense oligonucleotide therapy...
Tau protein
Advertisement
Voyager Shares Positive Six-Month Alzheimer’s Data
LEXINGTON, Mass., July 13, 2026 Voyager Therapeutics presented new six-month good laboratory practice (GLP) toxicology data demonstrating that its...
NeuroSense PrimeC Shows Positive Phase 2 Alzheimer’s Biomarker Data
CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...
AviadoBio Advances AVB-406 Gene Therapy for Alzheimer’s
LONDON, May 14, 2026 AviadoBio presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT)...
Alamar Launches Neuro 220 Panel for Precision Proteomics
Fremont, California, March 17, 2026 Alamar Biosciences, Inc. announced the launch of its NULISAseq™ Neuro 220 Panel, a next-generation...
Advertisement
